SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hikal gets EIR for pharmaceutical facility in Panoli

12 Dec 2019 Evaluate

Hikal has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its pharmaceutical manufacturing facility in Panoli in Gujarat. The five-day detailed inspection was carried out during the period September 09, 2019 - September 13, 2019. The inspection confirmed the site to be compliant with the principles and guidelines of Current Good Manufacturing Practices (CGMP).

The inspection concluded with 'Zero' 483 observations from the auditors. The establishment inspection report received on December 12, 2019 has classified the facility under NAI (No Action Indicated) for CGMP compliance.

Hikal is engaged in R&D, manufacturing and marketing of fine chemicals for the Pharmaceutical and Agrochemical industries.


Hikal Share Price

192.15 3.60 (1.91%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×